Payment overview · 2025
General Payments
$246.60
13 reported records · 10 companies
Healthcare provider profile · identity verified
John Michael Brooks, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLARION, PA · NPI 1801890421
Verified facts
What the public records show
CMS Open Payments records show John Michael Brooks, D.O. received $246.60 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.32 | 23.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.68 | 13.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.75 | 10.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.59 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.96 | 8.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.71 | 8.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $19.50 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.92 | 7.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.49 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.68 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.60 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 208 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 170 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
170 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 99 |
| Omeprazole | Omeprazole | 305 | 70 |
| Furosemide | Furosemide | 277 | 63 |
| Lisinopril | Lisinopril | 274 | 80 |
| Gabapentin | Gabapentin | 266 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 65 |
| Lorazepam | Lorazepam | 260 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 47 |
| Eliquis | Apixaban | 208 | 25 |
| Metformin Hcl | Metformin Hcl | 202 | 53 |
| Tramadol Hcl | Tramadol Hcl | 201 | 58 |
| Glimepiride | Glimepiride | 177 | 38 |
| Alprazolam | Alprazolam | 174 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 170 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 35 |
| Meloxicam | Meloxicam | 152 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 38 |
| Allopurinol | Allopurinol | 134 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 29 |
| Baclofen | Baclofen | 120 | 28 |
| Atenolol | Atenolol | 112 | 27 |
| Alendronate Sodium | Alendronate Sodium | 108 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 25 |
| Losartan Potassium | Losartan Potassium | 96 | 23 |
| Azithromycin | Azithromycin | 92 | 79 |
| Simvastatin | Simvastatin | 89 | 22 |
| Prednisone | Prednisone | 88 | 49 |
| Potassium Chloride | Potassium Chloride | 87 | 13 |
| Synthroid | Levothyroxine Sodium | 87 | 21 |
| Amoxicillin | Amoxicillin | 81 | 58 |
| Cephalexin | Cephalexin | 78 | 49 |
| Celecoxib | Celecoxib | 77 | 16 |
| Trulicity | Dulaglutide | 77 | 11 |
| Montelukast Sodium | Montelukast Sodium | 76 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 18 |
| Trazodone Hcl | Trazodone Hcl | 74 | suppressed |
| Ozempic | Semaglutide | 73 | 14 |
| Valsartan | Valsartan | 73 | 20 |
| Carvedilol | Carvedilol | 67 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Myrbetriq | Mirabegron | 63 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 13 |
| Xarelto | Rivaroxaban | 62 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Jardiance | Empagliflozin | 60 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 12 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | 12 |
| Mupirocin | Mupirocin | 41 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 18 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 13 |
| Etodolac | Etodolac | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.60 · 13 records | Lilly USA, LLC | CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, Ohtuvayre, PROLIA, TRELEGY ELLIPTA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error